138148-68-2

138148-68-2 structure

Name: N2'-Deacetyl-N2'-[3-(methyldithio)-1-oxopropyl]maytansine
Chemical Name: N2'-deacetyl-N2'-[3-(methyldithio)-1-oxopropyl]maytansine
CAS Number: 138148-68-2
Molecular Formula: C₃₆H₅₀ClN₃O₁₀S₂
Molecular Weight: 784.37900
Catalog: Signaling Pathways Antibody-drug Conjugate ADC Cytotoxin
Create Date: 2018-07-18 11:11:07
Modify Date: 2026-07-01 07:10:11
DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is about 3-10-fold more potent than the parent drug Maytansine, with IC50s ranging from 0.003 to 0.01 nM for DM1-SMe in a panel of human tumor cell lines[1].

Name	N2'-deacetyl-N2'-[3-(methyldithio)-1-oxopropyl]maytansine
Synonyms	DM1-SME; DM1-SSME; MAYTANSINOID DERIVATIVE WITH ADC LINKER. MAYTANSINE OR MERTANSINE OR EMTANSINE DERIVATIVE; N2'-DEACETYL-N2'-[3-(METHYLDITHIO)-1-OXOPROPYL]MAYTANSINE Maytansine, N2'-deacetyl-N2'-[3-(methyldithio)-1-oxopropyl] MaytansinoidDM4Impurity6 Mertansine 1H-Inden-2-ol,1-amino-2,3-dihydro-,(1R,4S) AP3 Intermidate 2 4,24-Dioxa-9,22-diazatetracyclo[19.3.1.1 10,14.03,5]hexacosane,maytansine deriv DM1-Sme DM1-SSMe DM1-SMe, 10 mM in DMSO Microtubule/Tubulin,ADC Payload,anti-tumor activity,tumor cell,DM1 SMe,DM1-SMe,inhibit,Inhibitor,maytansinoid,ADC Cytotoxin,DM-1-SMe,antibody-drug conjugate,DM1SMe (1S,2R,3S,5S,6R,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.11,1.03,]hexacosa-10,12,14,16,18-pentaen-6-yl (2S)-2-[N-methyl-3-(methyldisulfanyl)propanamido]propanoate Maytansinoid DM1 (14S,16S,32S,33S,2R,4S,10E,12E,14R)-86-Chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl N-methyl-N-(3-(methyldisulfaneyl)propanoyl)-L-alaninate maytansinoid derivative with ADC linker. Maytansine or mertansine or emtansine derivative

Description	DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is about 3-10-fold more potent than the parent drug Maytansine, with IC50s ranging from 0.003 to 0.01 nM for DM1-SMe in a panel of human tumor cell lines[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Antibody-drug Conjugate >> ADC Cytotoxin Signaling Pathways >> Cell Cycle/DNA Damage >> Microtubule/Tubulin Signaling Pathways >> Cytoskeleton >> Microtubule/Tubulin
Target	Maytansinoids
References	[1]. Wood AC, et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60(11):1860-1867. [2]. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107.

Precursor 0
DownStream 1
139504-50-0